If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,661.00    117.00 (7.58%)
Bid:
1,651.00
Ask:
1,656.00
Spread: 5.00 (0.303%)
Market Cap: £3.50b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Block listing Interim Review

1 Oct 2025 11:45

RNS Number : 6481B
Hikma Pharmaceuticals Plc
01 October 2025
 

Hikma Pharmaceuticals PLC

Block Listing Six Monthly Return

 

Date: 1 October 2025

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of schemes:

Hikma Pharmaceuticals PLC 2018 Management Incentive Plan ("MIP") and Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")

Period of return

From:

1 April 2025

To:

30 September 2025

Balance of unallotted securities under scheme(s) from previous return:

311,430 Ordinary Shares of 10 pence

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0 Ordinary Shares of 10 pence

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0 Ordinary Shares of 10 pence

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

311,430 Ordinary Shares of 10 pence

 

Name of contact:

Helen Middlemist

Telephone number of contact:

+44(0)20 7399 2760

 

 

 

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)

(LEI: 549300BNS685UXH4JI75)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRUPGACUUPAGUG
Date   Source Headline
6th Feb 20172:27 pmRNSTotal Voting Rights
6th Feb 201712:47 pmRNSHolding(s) in Company
18th Jan 20179:11 amRNSHikma receives approval for Sodium Oxybate
20th Dec 20163:24 pmRNSDirector/PDMR Shareholding
20th Dec 201611:00 amRNSHolding(s) in Company
20th Dec 201610:47 amRNSDirector/PDMR Shareholding
13th Dec 20161:46 pmRNSDirector/PDMR Shareholding
12th Dec 20164:06 pmRNSDirector/PDMR Shareholding
7th Dec 20169:35 amRNSDirector/PDMR Shareholding
6th Dec 20166:04 pmRNSTotal Voting Rights
5th Dec 201612:34 pmRNSDirector/PDMR Shareholding
2nd Dec 20165:42 pmRNSDirector/PDMR Shareholding
28th Nov 20169:59 amRNSDirector/PDMR Shareholding
22nd Nov 20167:00 amRNSHikma announces agreement with Vectura
16th Nov 201611:12 amRNSAdditional Listing
11th Nov 20162:48 pmRNSTotal Voting Rights
10th Nov 20167:00 amRNSTrading Statement
3rd Oct 20164:37 pmRNSBlock listing Interim Review
28th Sep 20165:12 pmRNSDirector/PDMR Shareholding
28th Sep 20169:09 amRNSDirector/PDMR Shareholding
26th Sep 201610:18 amRNSDirector/PDMR Shareholding
22nd Sep 20163:35 pmRNSDirector/PDMR Shareholding
20th Sep 20167:00 amRNSBoard appointment and succession
16th Sep 20165:32 pmRNSDirector/PDMR Shareholding
15th Sep 20164:36 pmRNSDirector/PDMR Shareholding
8th Sep 20165:18 pmRNSDirector/PDMR Shareholding
6th Sep 20165:52 pmRNSDirector/PDMR Shareholding
6th Sep 20164:02 pmRNSTotal Voting Rights
1st Sep 201610:18 amRNSDirector/PDMR Shareholding
26th Aug 20164:28 pmRNSDirector/PDMR Shareholding
26th Aug 20169:47 amRNSDirector/PDMR Shareholding
24th Aug 20167:00 amRNSHalf-year Report
10th Aug 20169:22 amRNSNotice of Results
3rd Aug 20165:18 pmRNSTrading Statement
21st Jul 20167:00 amRNSRegulatory approval of Hikma's colchicine upheld
20th Jul 20167:00 amRNSLaunch of Generic Xeloda® Tablets in the US
27th Jun 20167:01 amRNSDirector/PDMR Shareholding
27th Jun 20167:00 amRNSTotal Voting Rights
20th Jun 20167:00 amRNSDirector/PDMR Shareholding
7th Jun 20164:44 pmRNSTotal Voting Rights
24th May 20167:00 amRNSDirector/PDMR Shareholding
19th May 201612:15 pmRNSFurther re Colchicine Litigation
19th May 201610:17 amRNSDirector/PDMR Shareholding
18th May 20164:25 pmRNSDirector/PDMR Shareholding
12th May 20163:14 pmRNSResult of AGM
12th May 20167:00 amRNSAGM Statement
9th May 20164:05 pmRNSDirector/PDMR Shareholding
6th May 20169:12 amRNSDoc re. Bond Guarantor Group
29th Apr 20165:40 pmRNSDirector/PDMR Shareholding
28th Apr 20162:58 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.